⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216286 | 1.00 | — | — | |
| Iodide SCHEMBL2150737 | 0.97 | — | — | |
| Bromide SCHEMBL28499361 | 0.97 | — | — | |
| Iodide SCHEMBL14798201 | 0.87 | HRH1 (0.44) | — | |
| Iodide SCHEMBL14798203 | 0.87 | HRH1 (0.44) | — | |
| SCHEMBL28194856 | 0.80 | — | — | |
| SCHEMBL14141541 | 0.80 | HRH1 (0.42) | — | |
| SCHEMBL230753 | 0.78 | HRH1 (0.73) | — | |
| SCHEMBL41191 | 0.78 | L3MBTL1 (0.59) | — | |
| SCHEMBL29830938 | 0.78 | L3MBTL1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630525-B2 | Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | claimed |
| CN-112573998-B | Refining method of tertiary butanol | 万华化学集团股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-12630525-B2 | Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025134078-A1 | ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| WO-2025068354-A1 | SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| CN-112573998-B | Refining method of tertiary butanol | 万华化学集团股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |